RT Journal Article
SR Electronic
T1 Identification of 64 new risk loci for major depression, refinement of the genetic architecture and risk prediction of recurrence and comorbidities
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.24.22279149
DO 10.1101/2022.08.24.22279149
A1 Als, Thomas D.
A1 Kurki, Mitja
A1 Grove, Jakob
A1 Voloudakis, Georgios
A1 Therrien, Karen
A1 Tasanko, Elisa
A1 Nielsen, Trine Tollerup
A1 Naamanka, Joonas
A1 Veerapen, Kumar
A1 Levey, Daniel
A1 Bendl, Jaroslav
A1 Bybjerg-Grauholm, Jonas
A1 Zheng, Biao
A1 Demontis, Ditte
A1 Rosengren, Anders
A1 Athanasiadis, Georgios
A1 Bækved-Hansen, Marie
A1 Qvist, Per
A1 Walters, Bragi
A1 Thorgeirsson, Thorgeir
A1 Stefánsson, Hreinn
A1 Musliner, Katherine L
A1 Manikandan, Veera
A1 Farajzadeh, Leila
A1 Thirstrup, Janne
A1 Vilhjálmsson, Bjarni J.
A1 McGrath, John J.
A1 Mattheisen, Manuel
A1 Meier, Sandra
A1 ,
A1 Agerbo, Esben
A1 Stefánsson, Kári
A1 Nordentoft, Merete
A1 Werge, Thomas
A1 Hougaard, David M.
A1 Mortensen, Preben B.
A1 Stein, Murray
A1 Gelernter, Joel
A1 Hovatta, Iiris
A1 Roussos, Panos
A1 Daly, Mark J.
A1 Mors, Ole
A1 Palotie, Aarno
A1 Børglum, Anders D.
YR 2022
UL http://medrxiv.org/content/early/2022/08/25/2022.08.24.22279149.abstract
AB Major depression (MD) is a common mental disorder and a leading cause of disability worldwide. We conducted a GWAS meta-analysis of more than 1.3 million individuals, including 371,184 with MD, identifying 243 risk loci. Sixty-four loci are novel, including glutamate and GABA receptors that are targets for antidepressant drugs. Several biological pathways and components were enriched for genetic MD risk, implicating neuronal development and function. Intersection with functional genomics data prioritized likely causal genes and revealed novel enrichment of prenatal GABAergic neurons, astrocytes and oligodendrocyte lineages.We found MD to be highly polygenic, with around 11,700 variants explaining 90% of the SNP heritability. Bivariate Gaussian mixture modeling estimated that > 97% of risk variants for other psychiatric disorders (anxiety, schizophrenia, bipolar disorder and ADHD) are influencing MD risk when both concordant and discordant variants are considered, and nearly all MD risk variants influence educational attainment. Additionally, we demonstrated that MD genetic risk is associated with impaired complex cognition, including verbal reasoning, attention, abstraction and mental flexibility.Analyzing Danish nation-wide longitudinal data, we dissected the genetic and clinical heterogeneity, revealing distinct polygenic architectures across case subgroups of MD recurrency and psychiatric comorbidity and demonstrating two-to six-fold increases in absolute risks for developing comorbid psychiatric disorders among MD cases with the highest versus the lowest polygenic burden.The results deepen the understanding of the biology underlying MD and its progression and inform precision medicine approaches in MD.Competing Interest StatementB.J.V. is a member of the advisory board for Allelica. D.D. has received a speaker fee from Takeda. B.W., T.T., H.S. and K.S. are employed at deCODE/Amgen. M.J.D. is a founder of Maze Therapeutics and on the Scientific Advisory Board of RBNC Therapeutics. The other authors declare no competing interests.Funding StatementThe iPSYCH team was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003), the EU H2020 Program (Grant No. 667302, CoCA), NIH/NIMH (1U01MH109514-01 and 1R01MH124851-01 to ADB) and the Universities and University Hospitals of Aarhus and Copenhagen. The Danish National Biobank resource was supported by the Novo Nordisk Foundation. High-performance computer capacity for handling and statistical analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Center for Genomics and Personalized Medicine and the Centre for Integrative Sequencing, iSEQ, Aarhus University, Denmark (grant to ADB). The team at the Center for Disease Neurogenomics at Icahn School of Medicine at Mount Sinai was supported by the NIH (K08MH122911 to GV; T32MH087004 to KT; R01MH125246, R01AG067025, U01MH116442 and R01MH109677 to PR).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Scientific Ethics Committee in the Central Denmark Region gave ethical approval for this work. Ethics committee/IRB of the Danish Data Protection Agency gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary statistics from this publication are available at http://ipsych.au.dk/downloads/. All relevant iPSYCH data are available from the authors after approval by the iPSYCH Data Access Committee and can only be accessed on the secured Danish server (GenomeDK, https://genome.au.dk) as the data are protected by Danish legislation. For data access please contact: Anders D. Borglum. Data used for brain transcriptome model generation are available from PsychENCODE (overview of available data sets at http://resource.psychencode.org/); genotypes are controlled data and access instructions are provided at https://www.synapse.org/#!Synapse:syn4921369/wiki/477467. Note that some datasets have been indirectly accessed at the respective analytical websites (through the FUMA website). Please refer to these websites (e.g., for FUMA https://fuma.ctglab.nl/links and https://fuma.ctglab.nl/tutorial#datasets) for availability of datasets used in the respective follow-up analyses / lookups.